Gambaran Kejadian Efek Samping Obat (ESO) Dengan Kejadian Putus Obat Pada Pasien Tb Paru Di RSUD Luwuk
https://doi.org/10.33860/jik.v16i3.1533
Keywords:
Efek Samping Obat, Putus obat, TB ParuAbstract
Upaya pengendalian Tubeculosis (TB) menghadapi masalah bertambahnya kasus dan peningkatan TB Multi Drug Resisten (MDR) yang terjadi karena tertular jenis mikroba yang sudah resisten atau putus obat. Terjadinya putus obat, sebagian diakibatkan oleh adanya efek samping obat yang dirasakan oleh pasien. Tujuan penelitian ini adalah melihat gambaran efek samping obat yang dirasakan responden dengan kejadian putus obat. Metode penelitian ini adalah deskriptif, yaitu untuk memaparkan peristiwa penting yang terjadi pada responden. Instrumen yang digunakan berupa kuesioner dengan jawaban terbuka. Hasil penelitian menunjukkan efek samping obat TB MDR terbanyak adalah mual, muntah sebanyak 7 orang (77,8 %) kemudian disusul depresi sebanyak 5 orang (55,6%)%), sejalan dengan hasil penelitian dari Yang, et al. (2017) bahwa efek samping terbesar pada penelitiannya adalah gangguan pencernaan (18,4%) disusul oleh gangguan psikiatrik(5,5%). Alasan utama putus obat TB pada seorang responden adalah adanya efek samping obat berupa rasa mual, susah tidur dan berkeringat warna coklat. Sehingga tidak bisa bekerja pada jam yang ditentukan ditempatnya bekerja sebagai sopir. Efek samping obat pada penderita TB-MDR di RSUD Luwuk, cukup besar persentasenya, sehingga menyebabkan kejadian putus obat TB paru
References
Kemenkes RI. Pedoman Nasional Pengendalian Tuberkulosis-Keputusan Menteri Kesehatan Republik Indonesia Nomor 364. Kementeri Kesehat Republik Indones. 2011;(Pengendalian Tuberkulosis):110.
Tuberculosis Reports. Vol. 188, The Lancet. 1916. 1120–1121 p.
WHO. TB burden report 2018 [Internet]. Vol. 63, World Health Organization. 2018. 476 p. Available from: https://apps.who.int/iris/handle/10665/274453
Kemenkes RI. Hasil Riset Kesehatan Dasar Tahun 2018. Kementrian Kesehat RI. 2018;53(9):1689–99.
Kementerian Kesehatan. Rencana Aksi Nasional Public Private Mix Pengendalian Tuberkulosis Indonesia : 2011-2014. 2014;2011–4.
Gadallah MA, Mokhtar A, Rady M, El-Moghazy E, Fawzy M, Kandil SK. Prognostic factors of treatment among patients with multidrug-resistant tuberculosis in Egypt. J Formos Med Assoc. 2016;115(11):997–1003.
Seedat F, Hargreaves S, Nellums LB, Ouyang J, Brown M, Friedland JS. How effective are approaches to migrant screening for infectious diseases in Europe? A systematic review. Lancet Infect Dis. 2018;18(9):e259–71.
Janmeja AK, Aggarwal D, Dhillon R. Factors predicting treatment success in multi-drug resistant tuberculosis patients treated under programmatic conditions. Indian J Tuberc. 2018;65(2):135–9.
Pinho STR, Rodrigues P, Andrade RFS, Serra H, Lopes JS, Gomes MGM. Impact of tuberculosis treatment length and adherence under different transmission intensities. Theor Popul Biol. 2015;104(xxxx):68–77.
Li D, Ge E, Shen X, Wei X. Risk Factors of Treatment Outcomes for Multi-drug Resistant Tuberculosis in Shanghai, 2009-2012. Procedia Environ Sci. 2016;36:12–9.
Sukarma W. Laporan_Nasional_RKD2018_FINAL.pdf. Badan Penelitian dan Pengembangan Kesehatan. 2018. p. 198.
Kigozi G, Heunis C, Chikobvu P, Botha S, van Rensburg D. Factors influencing treatment default among tuberculosis patients in a high burden province of South Africa. Int J Infect Dis. 2017;54:95–102.
Javaid A, Shaheen Z, Shafqat M, Khan AH, Ahmad N. Risk factors for high death and loss-to-follow-up rates among patients with multidrug-resistant tuberculosis at a programmatic management unit. Am J Infect Control. 2017;45(2):190–3.
Notoatmodjo S. Metodologi Penelitian Kesehatan. Cetakan Ke. Jakarta: PT Rineka Cipta; 2012. 208+viii.
Moleong LJ. Metodologi Penelitian Kualitatif. 38th ed. Bandung: PT Remaja Rosdakarya; 2018. xiv, 410 ; 24 cm.
Toft AL, Dahl VN, Sifna A, Ige OM, Schwoebel V, Souleymane MB, et al. Treatment outcomes for multidrug- and rifampicin-resistant tuberculosis in Central and West Africa: a systematic review and meta-analysis. Int J Infect Dis. 2022;(xxxx).
Walker IF, Baral SC, Wei X, Huque R, Khan A, Walley J, et al. Multidrug-resistant tuberculosis treatment programmes insufficiently consider comorbid mental disorders. Int J Tuberc Lung Dis. 2017;21(6):603–9.
Akeju OO, Wright SCD, Maja TM. Lived experience of patients on tuberculosis treatment in Tshwane, Gauteng province. Heal SA Gesondheid [Internet]. 2017;22:259–67. Available from: https://doi.org/10.1016/j.hsag.2017.03.001
Yang TW, Park HO, Jang HN, Yang JH, Kim SH, Moon SH, et al. Side effects associated with the treatment of multidrug-resistant tuberculosis at a tuberculosis referral hospital in South Korea. Med (United States). 2017;96(28).
Khanal S, Elsey H, King R, Baral SC, Bhatta BR, Newell JN. Development of a patient-centred, psychosocial support intervention for multi-drug-resistant tuberculosis (MDR-TB) care in Nepal. PLoS One. 2017;12(1):1–16.
Direktorat Jenderal Pencegahan dan Pengendalian Penyakit Kementerian Kesehatan Republik Indonesia. Penatalaksanaan Tuberkulosis Resistan Obat di Indonesia. 2020. 6–7 p.
Deshmukh RD, Dhande DJ, Sachdeva KS, Sreenivas AN, Kumar AMV, Parmar M. Social support a key factor for adherence to multidrug-resistant tuberculosis treatment. Indian J Tuberc [Internet]. 2018;65(1):41–7. Available from: http://dx.doi.org/10.1016/j.ijtb.2017.05.003
Izhar MD, Butar MB, Hidayati F, Ruwayda R. Predictors and health-related quality of life with short form-36 for multidrug-resistant tuberculosis patients in Jambi, Indonesia: A case-control study. Clin Epidemiol Glob Heal [Internet]. 2021;12(September):100872. Available from: https://doi.org/10.1016/j.cegh.2021.100872
Suriyana IWD, Sjattar EL, Irwan AM, Hapsah H. Gambaran Putus Berobat Dari Sudut Pandang Penderita Dan Pengawas Minum Obat Di Kotamadya Parepare. J Ilm Keperawatan (Scientific J Nursing). 2018;4(2):93–100.
Pamungkas P, Rahardjo SS, Murti B. Developing Predictor Index of Multi-Drug Resistant Tuberculosis in Surakarta, Central Java. 2018;85.
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish with Poltekita : Jurnal Ilmu Kesehatan agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC BY-SA 4.0) that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
This work is licensed under a Creative Commons Attribution-ShareAlike 2.0 Generic License.
Poltekita : Jurnal Ilmu Kesehatan is licensed under a Creative Commons Attribution-Share Alike 4.0 International License
You are free to:
- Share, copy and redistribute the material in any medium or format
- Adapt, remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
